On May 26, 2023, Sun Pharmaceutical Industries Limited ('Company') has issued a letter to the Board of Directors of Taro Pharmaceutical Industries Ltd., Israel ('Taro') with a proposal containing a non-binding indication of interest to acquire all of the outstanding ordinary shares in Taro, other than any shares already held by the Company or its affiliates (For a purchase price of $38 per ordinary share, in cash the 'Proposal').\r\n\r\nCopy of the letter containing the Proposal is enclosed herewith as Annexure A. \r\n\r\nThis disclosure is being submitted pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.